Identification of novel VEB β-lactamase enzymes and their impact on avibactam inhibition

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 3183-3186

  Lahiri, Sushmita D ^a,b   Alm, Richard A ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b Macrolide Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; BETA LACTAMASE; BETA LACTAMASE VEB; EXTENDED SPECTRUM BETA LACTAMASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BACTERIAL PROTEIN; BETA LACTAMASE INHIBITOR; CEFTAZIDIME;

ACYLATION AND DEACYLATION; ARTICLE; BACTERIUM ISOLATE; DRUG BINDING; ENTEROBACTERIACEAE; ENZYME INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BACTERIAL PROTEINS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CEFTAZIDIME; ENTEROBACTERIACEAE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 84964950988     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00047-16     Document Type: Article

References (20)

1. Lahiri SD, Giacobbe RA, Johnstone MR, Alm RA. 2014. Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C beta-lactamase enzyme. J Antimicrob Chemother 69:2942-2946. http://dx.doi.org/10.1093/jac/dku237.
2. Fernea A, Galleni M, Frere JM. 2015. Kinetics of the interaction between avibactam and the CHE-1 class C beta-lactamase. J Antimicrob Chemother 70:951-953. http://dx.doi.org/10.1093/jac/dku442.
3. Crichlow GV, Kuzin AP, Nukaga M, Mayama K, Sawai T, Knox JR. 1999. Structure of the extended-spectrum class C beta-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 38:10256-10261. http://dx.doi.org/10.1021 /bi9908787.
4. Kim JY, Jung HI, An YJ, Lee JH, Kim SJ, Jeong SH, Lee KJ, Suh PG, Lee HS, Lee SH, Cha SS. 2006. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C betalactamase. Mol Microbiol 60:907-916. http://dx.doi.org/10.1111/j .1365-2958.2006.05146.x.
5. Mallo S, Perez-Llarena FJ, Kerff F, Soares NC, Galleni M, Bou G. 2010. A tripeptide deletion in the R2 loop of the class C beta-lactamase enzyme FOX-4 impairs cefoxitin hydrolysis and slightly increases susceptibility to beta-lactamase inhibitors. J Antimicrob Chemother 65:1187-1194. http: //dx.doi.org/10.1093/jac/dkq115.
6. Pimenta AC, Fernandes R, Moreira IS. 2014. Evolution of drug resistance: insight on TEM beta-lactamases structure and activity and betalactam antibiotics. Mini Rev Med Chem 14:111-122. http://dx.doi.org/10 .2174/1389557514666140123145809.
7. Page MG. 2008. Extended-spectrum beta-lactamases: structure and kinetic mechanism. Clin Microbiol Infect 14(Suppl 1):63-74. http://dx.doi .org/10.1111/j.1469-0691.2007.01863.x.
8. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. 2003. Outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 41:3542-3547. http://dx.doi.org/10.1128/JCM.41.8.3542-3547.2003.
9. Pasterán F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, Vazquez M, Procopio A, Tokumoto M, Cagnoni V. 2006. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother 50:3222-3224. http://dx.doi.org/10.1128 /AAC.00284-06.
10. Akinci E, Vahaboglu H. 2010. Minor extended-spectrum betalactamases. Expert Rev Anti Infect Ther 8:1251-1258. http://dx.doi.org/10 .1586/eri.10.119.
11. Bartolomé B, Jubete Y, Martinez E, de la Cruz F. 1991. Construction and properties of a family of pACYC184-derived cloning vectors compatible with pBR322 and its derivatives. Gene 102:75-78. http://dx.doi.org/10 .1016/0378-1119(91)90541-I.
12. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Poirel L, Rotimi VO, Mokaddas EM, Karim A, Nordmann P. 2001. VEB-1-like extended-spectrum beta-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg Infect Dis 7:468-470. http://dx.doi.org/10.3201 /eid0703.017322.
14. Lahiri SD, Mangani S, Durand-Reville T, Benvenuti M, De Luca F, Sanyal G, Docquier JD. 2013. Structural insight into potent broadspectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC betalactamases. Antimicrob Agents Chemother 57:2496-2505. http://dx.doi .org/10.1128/AAC.02247-12.
15. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and Dbeta-lactamases. J Biol Chem 288:27960-27971. http://dx.doi.org/10.1074/jbc.M113 .485979.
16. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A 109:11663-11668. http://dx.doi.org/10.1073/pnas.1205073109.
17. Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, Foster AN, Winkler ML, Gatta JA, Nichols WW, Testa R, Bonomo RA, Jacobs MR. 2015. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single beta-lactamases. Diagn Microbiol Infect Dis 82:65-69. http://dx.doi.org/10.1016/j.diagmicrobio.2015.02.003.
18. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL. 2010. Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics. Antimicrob Agents Chemother 54: 4159-4167. http://dx.doi.org/10.1128/AAC.00257-10.
19. Winkler ML, Papp-Wallace KM, Hujer AM, Domitrovic TN, Hujer KM, Hurless KN, Tuohy M, Hall G, Bonomo RA. 2015. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 59:1020-1029. http://dx.doi .org/10.1128/AAC.04238-14.
20. Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. 2014. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of binding pocket and implications for resistance. Antimicrob Agents Chemother 58:5704-5713. http://dx.doi.org/10.1128/AAC .03057-14.